Maxigen Biotech Valuation
| 1783 Stock | TWD 52.70 1.90 3.74% |
At this time, the firm appears to be overvalued. Maxigen Biotech secures a last-minute Real Value of NT$50.39 per share. The latest price of the firm is NT$52.7. Our model forecasts the value of Maxigen Biotech from analyzing the firm fundamentals such as Return On Equity of 0.0926, profit margin of 0.19 %, and Current Valuation of 3.32 B as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Maxigen Biotech's price fluctuation is very steady at this time. Calculation of the real value of Maxigen Biotech is based on 3 months time horizon. Increasing Maxigen Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Maxigen stock is determined by what a typical buyer is willing to pay for full or partial control of Maxigen Biotech. Since Maxigen Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Maxigen Stock. However, Maxigen Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 52.7 | Real 50.39 | Hype 52.7 |
The intrinsic value of Maxigen Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Maxigen Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Maxigen Biotech helps investors to forecast how Maxigen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Maxigen Biotech more accurately as focusing exclusively on Maxigen Biotech's fundamentals will not take into account other important factors: Maxigen Biotech Total Value Analysis
Maxigen Biotech is presently anticipated to have takeover price of 3.32 B with market capitalization of 5.02 B, debt of 16.62 M, and cash on hands of 390.34 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Maxigen Biotech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.32 B | 5.02 B | 16.62 M | 390.34 M |
Maxigen Biotech Investor Information
About 52.0% of the company shares are owned by insiders or employees . The book value of Maxigen Biotech was presently reported as 14.75. The company last dividend was issued on the 19th of August 2021. Maxigen Biotech had 1000:1050 split on the 7th of September 2023. Maxigen Biotech is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Maxigen Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Maxigen Biotech has an asset utilization ratio of 40.47 percent. This indicates that the Company is making NT$0.4 for each dollar of assets. An increasing asset utilization means that Maxigen Biotech is more efficient with each dollar of assets it utilizes for everyday operations.Maxigen Biotech Ownership Allocation
Maxigen Biotech maintains a total of 84.7 Million outstanding shares. Maxigen Biotech holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Maxigen Biotech Profitability Analysis
The company reported the revenue of 511.98 M. Net Income was 87.67 M with profit before overhead, payroll, taxes, and interest of 261.03 M.About Maxigen Biotech Valuation
Our relative valuation model uses a comparative analysis of Maxigen Biotech. We calculate exposure to Maxigen Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Maxigen Biotech's related companies.Maxigen Biotech Inc. engages in the development, manufacture, and marketing of biomedical and cosmeceutical skincare products in Taiwan and internationally. Maxigen Biotech Inc. was founded in 1998 and is based in Taoyuan, Taiwan. MAXIGEN BIOTECH is traded on Taiwan Stock Exchange in Taiwan.
8 Steps to conduct Maxigen Biotech's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Maxigen Biotech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Maxigen Biotech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Maxigen Biotech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Maxigen Biotech's revenue streams: Identify Maxigen Biotech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Maxigen Biotech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Maxigen Biotech's growth potential: Evaluate Maxigen Biotech's management, business model, and growth potential.
- Determine Maxigen Biotech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Maxigen Biotech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Maxigen Stock Analysis
When running Maxigen Biotech's price analysis, check to measure Maxigen Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Maxigen Biotech is operating at the current time. Most of Maxigen Biotech's value examination focuses on studying past and present price action to predict the probability of Maxigen Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Maxigen Biotech's price. Additionally, you may evaluate how the addition of Maxigen Biotech to your portfolios can decrease your overall portfolio volatility.